Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of zju-imb-z19 compound in drug for treating prostate cancer

A technology of ZJU-IMB-Z19, 1. ZJU-IMB-Z19, applied in the field of prostate cancer drugs, can solve problems such as upregulation and enzalutamide resistance

Active Publication Date: 2021-04-23
ZHEJIANG NORMAL UNIVERSITY +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Since AR and GR belong to the superfamily of nuclear receptors and have high structural similarities, studies have shown that when AR function is inhibited in prostate cancer patients treated with enzalutamide, the expression of GR is significantly up-regulated, thereby promoting About 50% of AR-regulated genes are re-expressed, causing the body to develop resistance to enzalutamide

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of zju-imb-z19 compound in drug for treating prostate cancer
  • Application of zju-imb-z19 compound in drug for treating prostate cancer
  • Application of zju-imb-z19 compound in drug for treating prostate cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1 ZJU-IMB-Z19 can inhibit the transcriptional function of endogenous and exogenous AR

[0036] will be 1.0 x 10 5 Cells / mL of PC-3 or LNCaP cell suspension were seeded in 24-well plates at 500 μL per well. When the cells grew to 60%, PC-3 cells were co-transfected with 100 ng PSA-luc, 20 ng AR-WT and 1 ng pCMV-Renilla plasmids per well (LNCaP cells were transfected with 100 ng PSA-luc and 1 ng pCMV-Renilla plasmids). 6 hours after transfection, the medium was changed to phenol red-free RPMI 1640 medium containing 10% charcoal-treated fetal bovine serum (FBS); 24 hours after transfection, one group was added with 5nM of dihydrotestosterone per well. The concentration of ZJU-IMB-Z19 or enzalutamide was added 1 μL each, and the other group was added 1 μL of DMSO (dimethyl sulfoxide) or the corresponding concentration of ZJU-IMB-Z19 or enzalutamide, and the culture was continued for 24 Hour. Finally, the medium was aspirated, and 100 μL of 1×PLB was added to each...

Embodiment 2

[0038] Example 2 ZJU-IMB-Z19 can inhibit the transcriptional activity of endogenous AR in LNCaP cells at the protein level without affecting the expression of endogenous AR.

[0039] Only detecting the inhibition of AR on downstream target genes by ZJU-IMB-Z19 by the dual-luciferase reporter system cannot fully explain the antagonistic effect of this compound on AR. The present invention next validates the results in Example 1 at the protein level. The specific operation steps are as follows: put 2.0×10 5 LNCaP cell suspension per mL was seeded in 6-well plates according to 2 ml per well. The medium used was RPMI 1640 medium containing 10% activated carbon-treated fetal bovine serum (FBS); cells were cultured in a carbon dioxide incubator at 37 degrees Celsius. Cells were cultured for 48 hours after drug addition, 8 μL of DMSO was added to the solvent group, 4 μL of DHT with a final concentration of 5 nM was added to each well of the other groups, and DMSO, enzalutamide, and...

Embodiment 3

[0041] Example 3 ZJU-IMB-Z19 can inhibit the transcriptional activity of endogenous AR in LNCaP cells at the mRNA level.

[0042] The effect of ZJU-IMB-Z19 on AR transcriptional activity is mainly reflected in the effect of ZJU-IMB-Z19 on the expression of AR downstream target genes. PSA (KLK3) is an important downstream target gene of AR. In Example 2, the effect of ZJU-IMB-Z19 on PSA protein expression was detected. There may be two reasons for the decrease in PSA protein expression. On the one hand, it may be due to AR transcription. The activity is inhibited, resulting in the down-regulation of AR target gene expression, which may also be caused by the degradation of PSA protein on the other hand. In order to further confirm that the down-regulation of PSA is due to the inhibition of AR transcription, the present invention uses qRT-PCR method to detect the effect of ZJU-IMB-Z19 on PSA at the mRNA level.

[0043] The pretreatment method of this experiment is exactly the sa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of ZJU-IMB-Z19 compound in the treatment of prostate cancer, the application of ZJU-IMB-Z19 as a dual-target antagonist of androgen receptor and glucocorticoid receptor, and the application of ZJU-IMB-Z19 Application of Z19 in preparation of medicament for treating prostate cancer. The present invention tests the inhibitory effect of multiple drug leads on the activity of androgen receptor and glucocorticoid receptor by constructing a reliable screening method for androgen receptor and glucocorticoid receptor antagonists, and finds that ZJU‑IMB‑Z19 It has an inhibitory effect on the transcriptional activity of the androgen receptor, and found that ZJU‑IMB‑Z19 has an inhibitory effect on the transcriptional activity of the glucocorticoid receptor, and finally found that ZJU‑IMB‑Z19 is a new type of androgen receptor and glucocorticoid Hormone receptor dual-target antagonist.

Description

technical field [0001] The invention relates to the field of prostate cancer drugs, in particular to the application of ZJU-IMB-Z19 compounds in the preparation of androgen receptor antagonists, glucocorticoid receptor antagonists and drugs for the treatment of prostate cancer. Background technique [0002] Androgen receptor (AR), a member of the nuclear receptor superfamily, is a ligand-activated transcription factor widely distributed in proliferating and non-proliferating tissues. AR protein has three domains: N terminal domain (NTD), DNA binding domain (DBD) and ligand binding domain (LBD). Among them, there is a hormone binding pocket (HBP) in the LBD binding domain. When androgen binds to HBP, Helix12 of AR undergoes a conformational change and becomes an Agonistic conformation, forming a dimerization structure, which enters the nucleus and is located in the nucleus. The Androgen Response Element (ARE) in the promoter region of the target gene binds to activate or inh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4709A61P35/00A61P15/16A61P13/08A61P17/10A61P17/08A61P17/14A61P5/46A61P17/00
CPCA61K31/4709A61P5/46A61P13/08A61P15/16A61P17/00A61P17/08A61P17/10A61P17/14A61P35/00
Inventor 周金明吴萌张荣玉黄晨超李晓宇岑山
Owner ZHEJIANG NORMAL UNIVERSITY